Flecainide and Risk of Skin Neoplasms: Results of a Large Nested Case-control Study in Spain and Denmark

Overview

Journal Front Pharmacol

Date 2023 Jan 9

PMID 36618916

Authors

Carlen Reyes

Luz M Leon-Munoz

Andrea Pistillo

Sigrun Alba Johannesdottir Schmidt

Kasper Bruun Kristensen

Diana Puente

Ana Llorente-Garcia

Consuelo Huerta-Alvarez

Anton Pottegard

Talita Duarte-Salles

Affiliations

Soon will be listed here.

Abstract

A previous study in Denmark suggested an increased melanoma risk associated with the use of flecainide. To study the association between flecainide use and the risk of melanoma and non-melanoma skin cancer in Spain and Denmark. We conducted a multi-database case-control study in (database/study period) Spain (SIDIAP/2005-2017 and BIFAP/2007-2017) and Denmark (Danish registries/2001-2018). We included incident cases of melanoma or non-melanoma skin cancer (NMSC) aged ≥18 with ≥2 years of previous data (≥10 years for Denmark) before the skin cancer and matched them to controls (10:1 by age and sex). We excluded persons with immunosuppression or previous cancer. We defined ever-use as any prescription fill and high-use as a cumulative dose of at least 200 g (reference: never-use). We categorized a cumulative dose for a dose-response assessment. We used conditional logistic regression to compute ORs (95% CI) adjusted for photosensitizing, anti-neoplastic, disease-specific drugs and comorbidities. The total numbers of melanoma/NMSC cases included were 7,809/64,230 in SIDIAP, 4,661/31,063 in BIFAP, and 27,978/152,821 in Denmark. In Denmark, high-use of flecainide was associated with increased adjusted ORs of skin cancer compared with never-use [melanoma: OR 1.97 (1.38-2.81); NMSC: OR 1.34 (1.15-1.56)]. In Spain, an association between high-use of flecainide and NMSC was also observed [BIFAP: OR 1.42 (1.04-1.93); SIDIAP: OR 1.19 (0.95-1.48)]. There was a non-significant dose-response pattern for melanoma in Denmark and no apparent dose-response pattern for NMSC in any of the three databases. We found similar results for ever-use of flecainide. Flecainide use was associated with an increased risk of melanoma (Denmark only) and NMSC (Denmark and Spain) but without substantial evidence of dose-response patterns. Further studies are needed to assess for possible unmeasured confounders.

References

Monk B . Basal cell carcinoma following amiodarone therapy. Br J Dermatol. 1995; 133(1):148-9. DOI: 10.1111/j.1365-2133.1995.tb02515.x. View

Dominguez-Berjon M, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarin M . [Constructing a deprivation index based on census data in large Spanish cities(the MEDEA project)]. Gac Sanit. 2008; 22(3):179-87. DOI: 10.1157/13123961. View

Thygesen L, Daasnes C, Thaulow I, Bronnum-Hansen H . Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011; 39(7 Suppl):12-6. DOI: 10.1177/1403494811399956. View

Macia-Martinez M, Gil M, Huerta C, Martin-Merino E, Alvarez A, Bryant V . Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain. Pharmacoepidemiol Drug Saf. 2020; 29(10):1236-1245. DOI: 10.1002/pds.5006. View

Pottegard A, Friis S, Christensen R, Habel L, Gagne J, Hallas J . Identification of Associations Between Prescribed Medications and Cancer: A Nationwide Screening Study. EBioMedicine. 2016; 7:73-9. PMC: 4909325. DOI: 10.1016/j.ebiom.2016.03.018. View

Gallelli L, Cione E, Siniscalchi A, Vasta G, Guerra A, Scaramuzzino A . Is there a Link between Non Melanoma Skin Cancer and Hydrochlorothiazide?. Curr Drug Saf. 2021; 17(3):211-216. DOI: 10.2174/1574886316666211103164412. View

Tuohimaa P, Pukkala E, Scelo G, Olsen J, Brewster D, Hemminki K . Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer. 2007; 43(11):1701-12. DOI: 10.1016/j.ejca.2007.04.018. View

Eberly L, Garg L, Yang L, Markman T, Nathan A, Eneanya N . Racial/Ethnic and Socioeconomic Disparities in Management of Incident Paroxysmal Atrial Fibrillation. JAMA Netw Open. 2021; 4(2):e210247. PMC: 7910819. DOI: 10.1001/jamanetworkopen.2021.0247. View

de Vries E, Trakatelli M, Kalabalikis D, Ferrandiz L, Ruiz-de-Casas A, Moreno-Ramirez D . Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study. Br J Dermatol. 2012; 167 Suppl 2:1-13. DOI: 10.1111/j.1365-2133.2012.11081.x. View

10.

Maoz K, Dvash S, Brenner S . Amiodarone-induced skin pigmentation and multiple basal-cell carcinomas. Int J Dermatol. 2010; 48(12):1398-400. DOI: 10.1111/j.1365-4632.2008.03819.x. View

11.

. Chlorinated drinking-water; chlorination by-products; some other halogenated compounds; cobalt and cobalt compounds. International Agency for Research on Cancer (IARC) Working Group, Lyon, 12-19 June 1990. IARC Monogr Eval Carcinog Risks Hum. 1991; 52:1-544. PMC: 7681469. View

12.

Robinson S, Zens M, Perry A, Spencer S, Duell E, Karagas M . Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol. 2013; 133(8):1950-5. PMC: 3655101. DOI: 10.1038/jid.2013.33. View

13.

Rasmussen P, Dalgaard F, Gislason G, Torp-Pedersen C, Piccini J, Dsouza M . Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study. Heart Rhythm. 2019; 17(4):560-566. DOI: 10.1016/j.hrthm.2019.11.025. View

14.

Recalde M, Rodriguez C, Burn E, Far M, Garcia D, Carrere-Molina J . Data Resource Profile: The Information System for Research in Primary Care (SIDIAP). Int J Epidemiol. 2022; 51(6):e324-e336. PMC: 9749711. DOI: 10.1093/ije/dyac068. View

15.

Friis S, Kesminiene A, Espina C, Auvinen A, Straif K, Schuz J . European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. Cancer Epidemiol. 2015; 39 Suppl 1:S107-19. DOI: 10.1016/j.canep.2015.08.003. View

16.

Schmidt S, Schmidt M, Mehnert F, Lemeshow S, Sorensen H . Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol. 2015; 29(8):1545-54. DOI: 10.1111/jdv.12921. View

17.

Pottegard A, Schmidt S, Wallach-Kildemoes H, Sorensen H, Hallas J, Schmidt M . Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2016; 46(3):798-798f. PMC: 5837522. DOI: 10.1093/ije/dyw213. View

18.

Su V, Hu Y, Chou K, Ou S, Lee Y, Lin E . Amiodarone and the risk of cancer: a nationwide population-based study. Cancer. 2013; 119(9):1699-705. DOI: 10.1002/cncr.27881. View

19.

Saginala K, Barsouk A, Aluru J, Rawla P, Padala S, Barsouk A . Epidemiology of Bladder Cancer. Med Sci (Basel). 2020; 8(1). PMC: 7151633. DOI: 10.3390/medsci8010015. View

20.

Pottegard A, Hallas J . New use of prescription drugs prior to a cancer diagnosis. Pharmacoepidemiol Drug Saf. 2016; 26(2):223-227. PMC: 5299521. DOI: 10.1002/pds.4145. View